Spectra Optia for automatic red blood cell exchange in people with sickle cell disease

2 Current practice

NICE medical technologies guidance on Spectra Optia for automatic red blood cell exchange in people with sickle cell disease describes the role of automated red cell exchange in managing sickle cell disease and should be referred to for further details.

The British Committee for Standards in Haematology 2015 guideline on the clinical use of apheresis procedures for the treatment of patients and collection of cellular therapy products recommends that elective red cell exchange should be considered in people with sickle cell disease for primary stroke prevention, secondary stroke prevention, elective surgery, painful crises in pregnancy, and in people with severe disease who cannot have hydroxycarbamide.